Black Diamond Therapeutics reports Q2 2021 cash of $263.5M; pipeline advancing

Black Diamond Therapeutics, Inc.

2021-Q2 EPS reported -$1.79

Cash, equivalents, and investments $263.5M as of June 30, 2021; expected to fund operations into 2023.
R&D expenses $26.7M vs $10.2M in Q2 2020; net cash used in operations $49.6M.
BDTX-189 Phase 1 data presented at ASCO; Phase 2 initiation on track for H2 2021 after FDA dialogue.
IND filings planned: BDTX-1535 in H1 2022, BRAP and FGFR programs in 2022.
Appointed Elizabeth Buck as CSO, Karsten Witt as interim CMO; Drs. Humphrey and Roberts departed; Mark Velleca added to Board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.